Abstract
The polyoma virus region expressed early in the lytic cycle encodes three proteins, or T-antigens, that together cause the infected cell to enter the cell cycle and so provide a suitable cellular environment for replication of the viral genome. Under some circumstances infection does not kill the cell, but the T-antigens are still produced, resulting in the cell becoming transformed and tumorigenic. Most of this transforming action is exerted by the middle T-antigen, which has the ability to convert established cell lines to an oncogenic state. Middle T is a membrane bound polypeptide that interacts with a number of the proteins used by tyrosine kinase associated receptors to stimulate mitogenesis, so MT can be considered as a permanently active analogue of a receptor. Through a defined series of interactions, MT assembles a large multi-protein complex at the cell membrane, consisting of MT, the core dimer of protein phosphatase 2A, an src-family tyrosine kinase, and via phosphotyrosines, ShcA, phosphatidylinositol (3′) kinase, and phospholipase Cγ-1. Tyrosine phosphorylation stimulates PI3K and PLCγ-1 enzymatic activity, and on ShcA creates binding sites for Grb2 with its associated Sos1 and Gab1. This activates p21ras, and hence, the MAP kinase cascade. Consequently, MT can be used as a model for studying cell transformation and growth factor receptor signalling pathways.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alessi DR, Cohen P . 1998 Curr. Opin. Genet. Dev. 8: 55–62
Aronheim A, Engelberg D, Li N, Al-Alawi N, Schlessinger J, Karin M . 1994 Cell 78: 949–961
Blaikie PA, Fournier E, Dilworth SM, Birnbaum D, Borg JP, Margolis B . 1997 J. Biol. Chem. 272: 20671–20677
Brewster CE, Glover HR, Dilworth SM . 1997 J. Virol. 71: 5512–5520
Campbell KS, Auger KR, Hemmings BA, Roberts TM, Pallas DC . 1995 J. Virol. 69: 3721–3728
Campbell KS, Ogris E, Burke B, Su W, Auger KR, Druker BJ, Schaffhausen BS, Roberts TM, Pallas DC . 1994 Proc. Natl. Acad. Sci. USA. 91: 6344–6348
Carpenter CL, Auger KR, Chanudhuri M, Yoakim M, Schaffhausen B, Shoelson S, Cantley LC . 1993 J. Biol. Chem. 268: 9478–9483
Chen Y, Freund R, Listerud M, Wang Z, Talmage DA . 1999 Oncogene 18: 139–148
Cheng SH, Harvey R, Espino PC, Semba K, Yamamoto T, Toyoshima K, Smith AE . 1988a EMBO J. 7: 3845–3855
Cheng SH, Piwnica Worms H, Harvey RW, Roberts TM, Smith AE . 1988b Mol. Cell. Biol. 8: 1736–1747
Cohen B, Liu YX, Druker B, Roberts TM, Schaffhausen BS . 1990a Mol. Cell. Biol. 10: 2909–2915
Cohen B, Yoakim M, Piwnica Worms H, Roberts TM, Schaffhausen BS . 1990b Proc. Natl. Acad. Sci. USA. 87: 4458–4462
Courtneidge SA, Goutebroze L, Cartwright A, Heber A, Scherneck S, Feunteun J . 1991 J. Virol. 65: 3301–3308
Courtneidge SA, Heber A . 1987 Cell 50: 1031–1037
Courtneidge SA, Smith AE . 1983 Nature 303: 435–439
Cullere X, Rose P, Thathamangalam U, Chatterjee A, Mullane KP, Pallas DC, Benjamin TL, Roberts TM, Schaffhausen BS . 1998 J. Virol. 72: 558–563
Dahl J, Thathamangalam U, Freund R, Benjamin TL . 1992 Mol. Cell. Biol. 12: 5050–5058
Dankort DL, Muller WJ . 2000 Oncogene 19: 1038–1044
Dilworth SM . 1995 Trends Microbiol. 3: 31–35
Dilworth SM, Brewster CE, Jones MD, Lanfrancone L, Pelicci G, Pelicci PG . 1994 Nature 367: 87–90
Dilworth SM, Griffin BE . 1982 Proc. Natl. Acad. Sci. USA. 79: 1059–1063
Dilworth SM, Hansson HA, Darnfors C, Bjursell G, Streuli CH, Griffin BE . 1986 EMBO J. 5: 491–499
Dilworth SM, Horner VP . 1993 J. Virol. 67: 2235–2244
Downward J . 1998 Curr. Opin. Genet. Dev. 8: 49–54
Druker BJ, Sibert L, Roberts TM . 1992 J. Virol. 66: 5770–5776
Dunant N, Ballmer Hofer K . 1997 Cell Signal 9: 385–393
Dunant NM, Messerschmitt AS, Ballmer Hofer K . 1997 J. Virol. 71: 199–206
Dunant NM, Senften M, Ballmer Hofer K . 1996 J. Virol. 70: 1323–1330
Eddy BE, Stewart SE, Berkeley W . 1958 Proc. Soc. Exp. Biol. and Med. 98: 848–851
Elliott J, Jones MD, Griffin BE, Krauzewicz N . 1998 Oncogene 17: 1797–1806
Erpel T, Courtneidge SA . 1995 Curr. Opin. Cell. Biol. 7: 176–182
Glenn GM, Eckhart W . 1995 J. Virol. 69: 3729–3736
Glover HR, Brewster CE, Dilworth SM . 1999 Oncogene 18: 4364–4370
Gorga FR, Riney CE, Benjamin TL . 1990 J. Virol. 64: 105–112
Gotoh N, Tojo A, Shibuya M . 1996 EMBO J. 15: 6197–6204
Goutebroze L, Dunant NM, Ballmer Hofer K, Feunteun J . 1997 J. Virol. 71: 1436–1442
Gross L . 1953 Proc. Soc. Exp. Biol. Med. 83: 414–421
Helmbrecht K, Zeise E, Rensing L . 2000 Cell Prolif. 33: 341–365
Hemmings BA . 1997 Science 275: 628–630
Horak ID, Kawakami T, Gregory F, Robbins KC, Bolen JB . 1989 J. Virol. 63: 2343–2347
Janssens V, Goris, J . 2001 Biochem. J. 353: 417–439
Kaplan DR, Whitman M, Schaffhausen B, Pallas DC, White M, Cantley L, Roberts TM . 1987 Cell 50: 1021–1029
Kennedy AP, Sekulic A, Irvin BJ, Nilson AE, Dilworth SM, Abraham RT . 1998 J. Biol. Chem. 273: 11505–11513
Kiefer F, Courtneidge SA, Wagner EF . 1994 Adv. Cancer Res. 64: 125–157
Kornbluth S, Sudol M, Hanafusa H . 1987 Nature 325: 171–173
Kypta RM, Hemming A, Courtneidge SA . 1988 EMBO J. 7: 3837–3844
Ling LE, Druker BJ, Cantley LC, Roberts TM . 1992 J. Virol. 66: 1702–1708
Ma YC, Huang J, Ali S, Lowry W, Huang XY . 2000 Cell 102: 635–646
Magnusson G, Nilsson MG, Dilworth SM, Smolar N . 1981 J. Virol. 39: 673–683
Marcellus R, Whitfield JF, Raptis L . 1991 Oncogene 6: 1037–1040
Markland W, Oostra BA, Harvey R, Markham AF, Colledge WH, Smith AE . 1986 J. Virol. 59: 384–391
Markland W, Smith AE . 1987 Biochim. Biophys. Acta. 907: 299–321
Matthews JT, Benjamin TL . 1986 J. Virol 58: 239–246
Meier R, Hemmings BA . 1999 J Recept Signal Transduct Res 19: 121–128
Meili R, Cron P, Hemmings BA, Ballmer Hofer K . 1998 Oncogene 16: 903–907
Messerschmitt AS, Dunant N, Ballmer Hofer K . 1997 Virology 227: 271–280
Metcalf D, Roberts TM, Cherington V, Dunn AR . 1987 EMBO J. 6: 3703–3709
Mumby M . 1995 Seminars in Cancer Biology 6: 229–237
Muser J, Kaech S, Moroni C, Ballmer Hofer K . 1989 Oncogene 4: 1433–1439
Nicholson PR, Dilworth SM . 2001 Viruses, Cell Transformation and Cancer: Perspectives in Medical Virology. Grand, RJA (ed) Elsevier Science B. V.: Amsterdam pp 85–128
Ogris E, Mudrak I, Mak E, Gibson D, Pallas DC . 1999 J. Virol. 73: 7390–7398
Pallas DC, Fu H, Haehnel LC, Weller W, Collier RJ, Roberts TM . 1994 Science 265: 535–537
Pallas DC, Morgan W, Roberts TM . 1989 J. Virol. 63: 4533–4539
Pallas DC, Shahrik LK, Martin BL, Jaspers S, Miller TB, Brautigan DL, Roberts TM . 1990 Cell 60: 167–176
Platko JD, Forbes ME, Varvayanis S, Williams MN, Brooks III SC, Cherington V, Yen A . 1998 Exp. Cell. Res. 238: 42–50
Rassoulzadegan M, Cowie A, Carr A, Glaichenhaus N, Kamen R, Cuzin F . 1982 Nature 300: 713–718
Rassoulzadegan M, Naghashfar Z, Cowie A, Carr A, Grisoni M, Kamen R, Cuzin F . 1983 Proc. Natl. Acad. Sci. USA 80: 4354–4358
Rodriguez Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J . 1994 Nature 370: 527–532
Ruediger R, Roeckel D, Fait J, Bergqvist A, Magnusson G, Walter G . 1992 Mol. Cell. Biol. 12: 4872–4882
Salcini AE, McGlade J, Pelicci G, Nicoletti I, Pawson T, Pelicci PG . 1994 Oncogene 9: 2827–2836
Scherneck S, Feunteun J . 1990 Arch Geschwulstforsch 60: 271–278
Senften M, Dilworth S, Ballmer Hofer K . 1997 J. Virol. 71: 6990–6995
Serunian LA, Auger KR, Roberts TM, Cantley LC . 1990 J. Virol. 64: 4718–4725
Su W, Liu W, Schaffhausen BS, Roberts TM . 1995 J. Biol. Chem. 270: 12331–12334
Summers SA, Lipfert L, Birnbaum MJ . 1998 Biochem. Biophys. Res. Comm. 246: 76–81
Talmage DA, Freund R, Young AT, Dahl J, Dawe CJ, Benjamin TL . 1989 Cell 59: 55–65
Templeton D, Voronova A, Eckhart W . 1984 Mol. Cell. Biol. 4: 282–289
Treisman R, Novak U, Favaloro J, Kamen R . 1981 Nature 292: 595–600
Ulug ET, Cartwright AJ, Courtneidge SA . 1992 J. Virol. 66: 1458–1467
Ulug ET, Hawkins PT, Hanley MR, Courtneidge SA . 1990 J. Virol. 64: 3895–3904
Urich M, Senften M, Shaw PE, Ballmer Hofer K . 1997 Oncogene 14: 1235–1241
van der Geer P, Wiley S, Gish GD, Pawson T . 1996 Curr. Biol. 6: 1435–1444
Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD . 1997 Trends Biochem. Sci. 22: 267–272
Walter G, Carbone A, Welch WJ . 1987 J. Virol. 61: 405–410
Walter G, Ruediger R, Slaughter C, Mumby M . 1990 Proc. Natl. Acad. Sci. USA. 87: 2521–2525
Xu W, Harrison SC, Eck MJ . 1997 Nature 385: 595–602
Yoakim M, Hou W, Liu Y, Carpenter CL, Kapeller R, Schaffhausen BS . 1992 J. Virol. 66: 5485–5491
Yonemoto W, Filson AJ, Queral Lustig AE, Wang JY, Brugge JS . 1987 Mol. Cell. Biol. 7: 905–913
Zhu W, Eicher A, Leber B, Andrews DW . 1998 Oncogene 17: 565–576
Acknowledgements
We are extremely grateful to Dr Nick Dibb for his help in writing this review. Work in the authors' laboratory is funded by the Cancer Research Campaign (UK), the BBSRC, and the AICR.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ichaso, N., Dilworth, S. Cell transformation by the middle T-antigen of polyoma virus. Oncogene 20, 7908–7916 (2001). https://doi.org/10.1038/sj.onc.1204859
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204859
Keywords
This article is cited by
-
Mouse models of breast cancer metastasis to bone
Cancer and Metastasis Reviews (2012)
-
The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K–Akt–mTOR signalling pathway
Nature Reviews Microbiology (2008)
-
Signal Transduction in Transgenic Mouse Models of Human Breast Cancer—Implications for Human Breast Cancer
Journal of Mammary Gland Biology and Neoplasia (2008)
-
Modeling Metastatic Breast Cancer in Mice
Journal of Mammary Gland Biology and Neoplasia (2007)
-
Chromosomal instability at a mutational hotspot in polyoma middle T-antigen affects its ability to activate the ARF-p53 tumor suppressor pathway
Oncogene (2006)